全文获取类型
收费全文 | 1395篇 |
免费 | 107篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 63篇 |
妇产科学 | 9篇 |
基础医学 | 172篇 |
口腔科学 | 8篇 |
临床医学 | 150篇 |
内科学 | 324篇 |
皮肤病学 | 19篇 |
神经病学 | 109篇 |
特种医学 | 155篇 |
外科学 | 99篇 |
综合类 | 31篇 |
一般理论 | 1篇 |
预防医学 | 103篇 |
眼科学 | 11篇 |
药学 | 103篇 |
1篇 | |
肿瘤学 | 150篇 |
出版年
2022年 | 13篇 |
2021年 | 25篇 |
2020年 | 7篇 |
2019年 | 21篇 |
2018年 | 26篇 |
2017年 | 28篇 |
2016年 | 21篇 |
2015年 | 24篇 |
2014年 | 31篇 |
2013年 | 35篇 |
2012年 | 50篇 |
2011年 | 54篇 |
2010年 | 35篇 |
2009年 | 24篇 |
2008年 | 56篇 |
2007年 | 62篇 |
2006年 | 59篇 |
2005年 | 53篇 |
2004年 | 48篇 |
2003年 | 37篇 |
2002年 | 46篇 |
2001年 | 44篇 |
2000年 | 28篇 |
1999年 | 30篇 |
1998年 | 27篇 |
1997年 | 31篇 |
1996年 | 38篇 |
1995年 | 27篇 |
1994年 | 29篇 |
1993年 | 26篇 |
1992年 | 29篇 |
1991年 | 36篇 |
1990年 | 29篇 |
1989年 | 40篇 |
1988年 | 30篇 |
1987年 | 38篇 |
1986年 | 32篇 |
1985年 | 22篇 |
1984年 | 28篇 |
1983年 | 22篇 |
1982年 | 28篇 |
1981年 | 16篇 |
1980年 | 20篇 |
1979年 | 17篇 |
1978年 | 18篇 |
1977年 | 18篇 |
1976年 | 16篇 |
1975年 | 6篇 |
1968年 | 4篇 |
1967年 | 4篇 |
排序方式: 共有1513条查询结果,搜索用时 0 毫秒
71.
72.
73.
Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma 总被引:5,自引:0,他引:5
BACKGROUND: Preclinically, paclitaxel given according to an intense bolus schedule has significant antitumor activity against human prostate carcinoma cell lines in SCID mice. The authors evaluated the feasibility and efficacy of weekly 1-hour infusion of paclitaxel in patients with metastatic hormone-refractory prostate carcinoma (HRPC). METHODS: A total of 18 patients with progressive metastatic HRPC were enrolled. Patients had to have no prior chemotherapy. Paclitaxel was infused weekly at a dose of 150 mg/m(2) over 1 hour for 6 weeks every 8 weeks. RESULTS: Eighteen patients with a median age of 68.5 years and a median prostate specific antigen (PSA) level of 82 ng/mL (range, 2.17-3196 ng/mL) were enrolled. The median number of prior hormone treatments was 2, and 12 patients on antiandrogens completed antiandrogen withdrawal. Ten of eighteen patients had bone-only metastasis and eight had metastasis to bone with lymph node and/or visceral metastasis. Seventeen patients received a total of 31 cycles (157 courses) and 1 patient refused chemotherapy. All patients were included in response evaluation. Of the 8 [corrected] patients with measurable disease, 4 achieved a major response, with 1 complete response (in the lung) and 3 partial responses (1 in the liver and 2 in the lymph nodes). Seven of eighteen patients (39%) had a PSA decline of >/=50%. The major high grade toxicity was peripheral neuropathy, with 6 patients (35%) developing Grade 3 toxicity. CONCLUSIONS: Weekly 1-hour paclitaxel has activity in patients with HRPC. The major toxicity is peripheral neuropathy. The minimal myelosuppressive effects make a modified schedule (lower doses on the same schedule or a shorter schedule of the same dose) attractive for future combination chemotherapy trials. 相似文献
74.
75.
SM Dyer IS de la Lande DB Frewin & RJ Head 《Clinical and experimental pharmacology & physiology》1998,25(3-4):246-251
1. 5-Hydroxytryptamine (5-HT) exerts both contractile and relaxant effects in the marmoset isolated aorta, actions that are unaffected by the 5-HT2 antagonist ketanserin. The aim of the present study was to define the receptors mediating the contractile activity of 5-HT in the marmoset aorta.
2. Contractile responses were elicited in aortic rings that were either: (i) precontracted submaximally with the thromboxane A2 agonist U44069 in order to amplify the responses; or (ii) exposed to N ω -nitro- L -arginine (100 μmol/L) plus LY 53857 (0.1 μmol/L; a 5-HT2 receptor antagonist shown previously to inhibit relaxation). The effect of 5-HT on adenosine 3',5'-cyclic monophosphate (cAMP) formation was also investigated.
3. The effects of agonists and antagonists comprised: (i) agonist potencies in the order 5-carboxamidotryptamine > 5-HT > sumatriptan > 8-hydroxy-2-(di- n -propylamino)tetralin; (ii) inhibition of contractile action of 5-HT by the 5-HT1D antagonist GR 127935; (iii) a contractile response to methysergide; (iv) a lack of effect of tropisetron, an antagonist of 5-HT3 and 5-HT4 receptors; and (v) inhibition of forskolin-stimulated cAMP formation by 5-HT (in the presence of LY 53857), indicative of negative coupling to adenylate cyclase.
4. The above effects fulfil the criteria for a 5-HT1 -like receptor. In view of the previous finding that this contractile response is insensitive to ketanserin, it is concluded that the contractile effects of 5-HT in the marmoset aorta are mediated exclusively by a 5-HT1 -like receptor. 相似文献
2. Contractile responses were elicited in aortic rings that were either: (i) precontracted submaximally with the thromboxane A
3. The effects of agonists and antagonists comprised: (i) agonist potencies in the order 5-carboxamidotryptamine > 5-HT > sumatriptan > 8-hydroxy-2-(di- n -propylamino)tetralin; (ii) inhibition of contractile action of 5-HT by the 5-HT
4. The above effects fulfil the criteria for a 5-HT
76.
Flaherty FJ 《Proceedings of the National Academy of Sciences of the United States of America》1979,76(10):4765-4767
A spacelike hypersurface (condimension 1) in a Lorentzian manifold is called a maximal surface if it extremizes the hypervolume functional. Although maximal surfaces are superficially analogous to minimal hypersurfaces in Riemannian geometry, their properties can be dramatically different, as can be seen from the validity of Bernstein's theorem in all dimensions [Cheng, S.-Y. & Yau, S.-T. (1976) Ann. Math. 104, 407-419]. Here we establish a point of contact between maximal surfaces and minimal surfaces by solving the Dirichlet problem for acausal boundary data but using boundary curvature conditions similar to those of H. Jenkins and J. Serrin [(1968) J. Reine Angew. Math. 229, 170-187]. 相似文献
77.
78.
Pulmonary fibrosis is often the end stage of chronic, persistent, low-level lung injury, either of known or unknown cause. The most severe form of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF), a disease process of unknown aetiology and one that often leads to respiratory failure and death. At present there are no proven or effective drug therapies for IPF. Recent advances in understanding of disease pathogenesis have focused attention on drug targeting of fibrogenic pathways, as opposed to traditional anti-inflammatory approaches. In this report, the present status of drug development of a number of emerging antifibrotic strategies and agents that may prove more effective in the therapy of this progressive, debilitating and fatal disease are reviewed. 相似文献
79.
Fukuoka J Franks TJ Colby TV Flaherty KR Galvin JR Hayden D Gochuico BR Kazerooni EA Martinez F Travis WD 《The American journal of surgical pathology》2005,29(7):948-954
Peribronchiolar metaplasia (PBM) is a histologic lesion consisting of peribronchiolar metaplasia (PBM) of bronchiolar-type epithelium. Although widely recognized, PBM has received little attention in the pathologic literature and is not known to have clinical significance. We identified 15 cases in which PBM was the only major histologic finding in surgical lung biopsies from patients with interstitial lung disease (PBM-ILD), and we reviewed the clinical, imaging, and pathologic findings. The mean age was 57 years (range, 44-74 years) with 13 females and 2 males. One patient had been a welder with fume and asbestos exposure; another had pigeon exposure. Smoking history was available for 13 patients: three current smokers, one cocaine user, two former smokers, and seven never smokers. Three patients had collagen vascular disease. One had elevated serum antinuclear antibody titers. Pulmonary function data were available for 10 patients: one obstructive, five restrictive, two mixed obstructive and restrictive, and two normal. Computerized tomography in 7 patients showed mosaic attenuation in 3 patients and air trapping in 1 patient; no bronchiectasis, septal lines, or honeycombing were seen in any cases. All 11 patients with available follow-up are alive; 4 of them have experienced symptomatic improvement (follow-up, 0.6-6.9 years; mean, 2.4 years). PBM was found focally in other interstitial lung diseases, which were assessed for this lesion: 59% of usual interstitial pneumonia (17 of 29), 50% of nonspecific interstitial pneumonia (10 of 20), desquamative interstitial pneumonia (3 of 6), hypersensitivity pneumonitis (9 of 18), and 11% of respiratory bronchiolitis (2 of 18). In summary, PBM is a common histologic finding in various interstitial lung disorders. It is rarely the sole major lung biopsy finding in patients presenting with interstitial lung disease (PBM-ILD). Patients are mostly older women, with mild symptoms and CT findings. Survival appears to be favorable. 相似文献
80.
Flaherty E 《Nursing standard (Royal College of Nursing (Great Britain) : 1987)》2005,19(45):78, 80, 82-783 passim
AIM: To examine the views of patients with a diagnosis of venous insufficiency who had experienced at least one episode of venous ulceration that had been treated and healed. METHOD: Ten participants (five female, five male) were recruited from a community-based healed leg ulcer clinic. In-depth semi-structured interviews were conducted with participants. The interview data were then transcribed and analysed for themes and patterns. FINDINGS: Three themes emerged: symptoms, treatment and coping mechanisms, each with sub-themes. Long-term pain, changes in body image, limitations to lifestyle and difficulties with treatment were described by participants. Level of knowledge was found to be related to the coping measures demonstrated by participants, which included non-acceptance and normalisation. CONCLUSION: Future developments and reviews of existing services in the overall management of patients with venous ulceration need to include a shift of emphasis to encompass the chronic nature of the underlying disease, with socially acceptable interventions aimed at controlling or limiting the consequences to the patient. 相似文献